Suppr超能文献

细胞表面CD200可能预测父源单个核白细胞免疫疗法治疗人类复发性流产的疗效。

Cell-surface CD200 may predict efficacy of paternal mononuclear leukocyte immunotherapy in treatment of human recurrent pregnancy loss.

作者信息

Clark David A

机构信息

Department of Medicine, Molecular Medicine & Pathology, Obstetrics and Gynecology, McMaster University, Hamilton, ON, Canada.

出版信息

Am J Reprod Immunol. 2009 Jan;61(1):75-84. doi: 10.1111/j.1600-0897.2008.00665.x.

Abstract

PROBLEM

The allogeneic leukocytes in transfused blood can modulate the recipient's immune system so as to induce TGF-beta-producing suppressor cells, and the cell-surface CD200 tolerance-signaling molecule on mononuclear dendritic cells is required for this effect. A subset of couples with unexplained recurrent pregnancy loss appears to benefit from transfusion of allogeneic paternal blood leukocytes (LIT), and considerable effort has been devoted to characterizing those who may benefit. Some data has been accumulated for LIT as sole therapy in patients with classical spontaneous abortions with respect to dose-response, duration of protection, need for boosting, excluding patients with autoimmunity, and inefficacy of paternal mononuclear cells stored at 4 degrees C overnight before use which causes loss of cell-surface CD200. Recent data emphasize an important role of expression of the CD200 tolerance-signaling molecule on cells used to prevent abortions both in mice and humans.

METHOD OF STUDY

An observational study of outcome as a function of the number of CD200(+) paternal mononuclear cells was performed. Fourteen patients constituted the pilot group. Patients with autoimmunity who had failed inspite of treatment with IVIG + Heparin + Aspirin +/- Prednisone were allowed to have paternal mononuclear cells added to their therapy. CD200 on purified paternal blood mononuclear cells was measured by flow cytometry.

RESULTS

The number of CD200(+) cells administered was significantly greater in women achieving pregnancy (39.2 x 10(6) versus 20.8 x 10(6), P < 0.025) and in those who achieved a live birth (50.2 x 10(6) versus 20.8 x 10(6), P < 0.005) compared to those who did not achieve pregnancy, and % of paternal cells that were CD200(+) was greater (11-12.5% versus 5.6%, P < 0.01). Amongst those achieving pregnancy which failed, the CD200(+) cell dose was not significantly different from the non-pregnant group (30.5 x 10(6) versus 20.8 x 10(6)).

CONCLUSION

The number of CD200(+) paternal mononuclear leukocytes may be an important determinant of subsequent reproductive outcome in a subset of patients. A lower % CD200(+) cell number may also reflect hitherto unappreciated paternal factors bearing on reproductive success. It is feasible to recruit women to enter observational studies and to obtain useful data as a foundation for further studies. More complete patient characterization in a larger study is needed.

摘要

问题

输血中的同种异体白细胞可调节受者的免疫系统,从而诱导产生转化生长因子β的抑制细胞,单核树突状细胞上的细胞表面CD200耐受信号分子对于此效应是必需的。一部分原因不明的复发性流产夫妇似乎可从输注同种异体父源血液白细胞(白细胞免疫疗法)中获益,并且人们已投入大量精力来确定哪些人可能会从中受益。关于白细胞免疫疗法作为经典自然流产患者的单一疗法,在剂量反应、保护持续时间、是否需要加强治疗、排除自身免疫性疾病患者以及使用前在4℃下过夜保存的父源单核细胞无效(这会导致细胞表面CD200丢失)等方面已积累了一些数据。最近的数据强调了CD200耐受信号分子在用于预防小鼠和人类流产的细胞上表达的重要作用。

研究方法

进行了一项观察性研究,观察结果作为CD200(+)父源单核细胞数量的函数。14名患者组成了试验组。尽管接受了静脉注射免疫球蛋白+肝素+阿司匹林+/-泼尼松治疗但仍失败的自身免疫性疾病患者,被允许在其治疗中加入父源单核细胞。通过流式细胞术测量纯化的父源血液单核细胞上的CD200。

结果

与未怀孕的女性相比,成功怀孕的女性(39.2×10⁶对20.8×10⁶,P<0.025)和活产女性(50.2×10⁶对20.8×10⁶,P<0.005)给予的CD200(+)细胞数量显著更多,并且父源细胞中CD200(+)的百分比更高(11 - 12.5%对5.6%,P<0.01)。在成功怀孕但随后流产的女性中,CD200(+)细胞剂量与未怀孕组无显著差异(30.5×10⁶对20.8×10⁶)。

结论

CD200(+)父源单核白细胞的数量可能是一部分患者后续生殖结局的重要决定因素。较低的CD200(+)细胞百分比也可能反映了迄今未被认识到的影响生殖成功的父源因素。招募女性参与观察性研究并获得有用数据作为进一步研究的基础是可行的。需要在更大规模的研究中对患者进行更全面的特征描述。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验